DCH Auriga to provide Hong Kong-approved medical treatments to Greater Bay Area patients

DCH Auriga announced their strategic cooperation with Hong Kong Integrated Oncology Centre (“HKIOC”) and Hong Kong cancer treatment centre in support of a National State Council initiative to help patients in the Hong Kong-Guangzhou-Macao Greater Bay Area (“GBA”) access pharmaceuticals and medical devices that are fully approved for use in Hong Kong but not registered in mainland China. Under the strategic partnership, DCH Auriga and HKIOC will support Zhongshan Chenxinghai Hospital to offer the newly available treatments, with Auriga supporting the product supply chain. The partners share a goal of introducing 10 of the newly approved treatments at the hospital during in 2022.

The cooperation will promote greater connectivity across the region, benefitting both patients and the medical community. In addition to providing new care options, case reports can be applied towards clinical trial requirements to help facilitate the treatment’s eventual registration and adoption across mainland China. There are likely more than 200 treatments with the potential to qualify under the scheme with nearly 25 medicines and medical devices already approved by the Food and Drug Administration and Health Commission of Guangdong Province, including advanced cancer treatments.

Richard Holloway, the head of DCH Auriga’s Greater China business, emphasised the company’s dedication to building partnerships in the region in support of the new scheme. “As a healthcare distributor that works closely with Hong Kong’s public and private health system as well as leading global pharmaceutical companies, DCH Auriga has extensive experience not only managing medical supply chains, but in supporting ethical advocacy programs and product registration. We are uniquely positioned to facilitate information sharing, the application process and the physical supply chain in support of this important initiative.”